Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CTSC | P53634 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 6/20 | 0.34 |
| ▸ | RAB9A | P51151 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4350616 | 0.87 | KIF11 (0.41) | MMP1MMP2MMP9MMP12SLC1A3 | |
| SCHEMBL9878919 | 0.86 | KIF11 (0.40) | MMP1MMP2MMP9MMP12SLC1A3 | |
| SCHEMBL58410 | 0.85 | MMP2 (0.40) | MMP1MMP2MMP9MMP12SLC1A3 | |
| SCHEMBL8430877 | 0.83 | MMP1 (0.38) | MMP1MMP2MMP9MMP12SLC1A3 | |
| SCHEMBL1897993 | 0.83 | MMP1 (0.41) | MMP1MMP2MMP9MMP12SLC1A3 | |
| SCHEMBL6062940 | 0.81 | KIF11 (0.42) | MMP1MMP2MMP9MMP12SLC1A3 | |
| SCHEMBL29159324 | 0.81 | MMP1 (0.40) | MMP1MMP2MMP9MMP12SLC1A3 | |
| SCHEMBL5680233 | 0.81 | ALPI (0.51) | SLC1A3SLC1A2SLC1A1CTSCHPGD | |
| SCHEMBL5801530 | 0.80 | DPP7 (0.42) | MMP1MMP2MMP9MMP12SLC1A3 | |
| SCHEMBL3399442 | 0.79 | MMP1 (0.43) | MMP1MMP2MMP9MMP12SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197954-A1 | SYNTHESIS OF SPHINGOSINES AND THEIR DERIVATIVES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-08-05 | — | — | US | claimed |
| WO-2008030840-A2 | SYNTHESIS OF SPHINGOSINES AND THEIR DERIVATIVES | EMORY UNIVERSITY (US) | 2008-03-13 | — | — | WO | claimed |
| EP-1301279-B1 | ADSORPTION METHOD AND LIGANDS | CYTIVA BIOPROCESS R & D AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| US-7960589-B2 | Synthesis of sphingosines and their derivatives | EMORY UNIVERSITY (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100197954-A1 | SYNTHESIS OF SPHINGOSINES AND THEIR DERIVATIVES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-08-05 | — | — | US | disclosed |
| WO-2008030840-A2 | SYNTHESIS OF SPHINGOSINES AND THEIR DERIVATIVES | EMORY UNIVERSITY (US) | 2008-03-13 | — | — | WO | disclosed |
| US-7214321-B2 | Adsorption method and ligands | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2007-05-08 | — | — | US | disclosed |
| EP-1345694-B1 | A METHOD FOR THE MANUFACTURE OF COMPOSITIONS CONTAINING LOW CONCENTRATIONS OF SALTS | GE HEALTHCARE BIO SCIENCES AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-6852230-B2 | Method for the manufacture of compositions containing low concentrations of salts | AMERSHAM BIOSCIENCES AB (SE) | 2005-02-08 | — | — | US | disclosed |
| US-20040256324-A1 | Adsorption method and ligands | CYTIVA BIOPROCESS R&D AB (SE) | 2004-12-23 | — | — | US | disclosed |
| US-20040050784-A1 | Method for the manufacture of compositions containing low concentrations of salts | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2004-03-18 | — | — | US | disclosed |
| EP-1345694-A2 | A METHOD FOR THE MANUFACTURE OF COMPOSITIONS CONTAINING LOW CONCENTRATIONS OF SALTS | Amersham Biosciences AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| EP-1301279-A2 | ADSORPTION METHOD AND LIGANDS | Amersham Pharmacia Biotech AB (SE) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002053288-A2 | A METHOD FOR THE MANUFACTURE OF COMPOSITIONS CONTAINING LOW CONCENTRATIONS OF SALTS | AMERSHAM BIOSCIENCES AB (SE) | 2002-07-11 | — | — | WO | disclosed |
| WO-2002005959-A2 | ADSORPTION METHOD AND LIGANDS | AMERSHAM BIOSCIENCES AB (SE) | 2002-01-24 | — | — | WO | disclosed |
| US-5834460-A | FOR TREATMENT OF BRAIN OR PSYCHOLOGICAL DISORDERS, ALZHEIMER*S DISEASE, MENTAL RETARDATION OR AUTISM | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| CN-1121713-A | serine derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1996-05-01 | — | — | CN | disclosed |
| EP-0696586-A1 | SERINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197954-A1 | SYNTHESIS OF SPHINGOSINES AND THEIR DERIVATIVES | SPHK1, SPHK2, S1PR2 | MMP1 4881/4885MMP2 4652/4885MMP9 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.